April 28th 2021
By Tony Hagen
How much muscle did Congress invest in a pair of bills recently signed by President Biden? The answer may lie in your willingness to believe.
April 24th 2021
Medicinal packaging shouldn't remind patients that they have a condition, according to Samsung Bioepis.
April 23rd 2021
The European Union is a diverse market with pockets of biosimilar resistance but also cost-saving triumphs, panelists said at the Biosimilar Medicines Virtual Summit 2021.
April 19th 2021
Anticipating roughly $26 million in annual savings, British Columbia's public payer PharmaCare is switching patients away from originator Humira.
April 15th 2021
New York Medicaid achieved 78% to 94% biosimilar utilization for 4 originator brands during a focused effort in 2019.
April 14th 2021
Opinions are diverse on how best to clear the obstructions to biosimilar market entry and patient access.
April 12th 2021
By Skylar Jeremias
To overcome provider and patient preferences for brand originators, there has to be more of an incentive to use biosimilars, explains Nedzad Pojskic, PhD, MSc, Green Shield Canada.
April 10th 2021
By Paul Cornes, BM, BCH, MA, MRCP, FRCR
An internationally recognized authority on biosimilar development discusses varieties of copy biologics in India and the need to distinguish these from true biosimilars.
April 9th 2021
The latest e-book from The Center for Biosimilars® offers insightful content on patient education, biosimilar development, and regulatory issues.
March 26th 2021
A renowned expert on the life sciences industry in the United Kingdom provides an insightful look at Brexit and the importance for the pharmaceutical sector.
